Pharming Group (OTCMKTS:PHGUF) Sees Strong Trading Volume – Should You Buy?

Pharming Group NV (OTCMKTS:PHGUF) saw strong trading volume on Tuesday . 20,000 shares were traded during mid-day trading, an increase of 203% from the previous session’s volume of 6,591 shares.The stock last traded at $1.24 and had previously closed at $1.6350.

Pharming Group Price Performance

The company has a market cap of $832.13 million, a P/E ratio of 62.03 and a beta of 0.55. The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.03 and a current ratio of 2.59. The business’s fifty day moving average is $1.57 and its two-hundred day moving average is $1.65.

Pharming Group (OTCMKTS:PHGUF) last issued its earnings results on Thursday, May 7th. The biotechnology company reported ($0.01) EPS for the quarter. Pharming Group had a return on equity of 4.68% and a net margin of 3.30%.The company had revenue of $72.45 million for the quarter, compared to analysts’ expectations of $92.06 million.

About Pharming Group

Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.

Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.